Support the strategic goals of the Inflammation & Immunology Business Unit by driving optimal launch and patient access for Brepocitinib through the generation, integration, and translation of robust value and evidence.
Base: $176,600.00 - $294,300.00; Bonus/Equity: 20.0% bonus target; Benefits: Comprehensive and generous benefits and programs
Must-have
Nice-to-have
Permanent work authorization in the United States